Department of Gastroenterology, Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India
Research Article
Efficacy and Safety of Tenofovir Alafenamide in Treatment Naive Patients with Hepatitis B-Virus Related Decompensated Cirrhosis: A Prospective Observational Study
Author(s): Sanjeev Jha*, Ravikant Kumar, Saurabh Kumar, Ravi Keshri, Aditya V. Singh, Gaurav Kumar and Samir S. Bhagwat
Background: The effect of Tenofovir Alafenamide (TAF) therapy on viral suppression and hepatic function in patients of Hepatitis B Virus (HBV) related decompensated cirrhosis is
not known. Aim of this study was to evaluate the efficacy and safety of TAF therapy in these patients.
Methods: We analyzed 55 consecutive HBV-infected treatment naive patients with decompensated cirrhosis treated with 25 mg/day TAF and evaluated the treatment outcomes.
Treatment efficacy was evaluated by measuring virological, serological, biochemical responses and changes in hepatic function over period of 6 month.
Results: At month 6, undetectable HBV-DNA level, HBeAg loss, HBeAg seroconversion and ALT normalization was seen in 65.2%, 22.2%, 5.5% and 74.5% patients respectively.
Virological and biochemical responses were simi.. Read More»
DOI:
10.37421/cgj.2021.6.143
Clinical Gastroenterology Journal received 33 citations as per Google Scholar report